3 US Penny Stocks With Market Caps Over $30M To Watch

As the U.S. stock market experiences slight declines with investors eagerly awaiting the December jobs report, attention turns to the potential impact on interest rates and economic resilience. In this context, penny stocks—often smaller or newer companies—remain a relevant investment area due to their affordability and growth potential. Despite being considered a throwback term, these stocks can offer significant opportunities when backed by strong financials, presenting intriguing prospects for investors seeking hidden value in today's market landscape.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Financial Health Rating
BAB (OTCPK:BABB)	$0.81	$5.88M	★★★★★★
Inter & Co (NasdaqGS:INTR)	$4.25	$1.87B	★★★★☆☆
Kiora Pharmaceuticals (NasdaqCM:KPRX)	$3.7257	$11.18M	★★★★★★
QuantaSing Group (NasdaqGM:QSG)	$3.08	$102.23M	★★★★★★
ZTEST Electronics (OTCPK:ZTST.F)	$0.32	$11.77M	★★★★★★
Permianville Royalty Trust (NYSE:PVL)	$1.41	$46.53M	★★★★★★
Imperial Petroleum (NasdaqCM:IMPP)	$3.20	$97.06M	★★★★★★
Golden Growers Cooperative (OTCPK:GGRO.U)	$4.50	$67.38M	★★★★★★
Smith Micro Software (NasdaqCM:SMSI)	$1.37	$24.3M	★★★★★☆
Safe Bulkers (NYSE:SB)	$3.45	$368.38M	★★★★☆☆

Click here to see the full list of 728 stocks from our US Penny Stocks screener.

We'll examine a selection from our screener results.

Giftify (NasdaqCM:GIFT)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Giftify, Inc. owns and operates a restaurant deal space in the United States with a market cap of $31.41 million.

Operations: The company generates revenue of $86.44 million from its Direct Marketing segment.

Market Cap: $31.41M

Giftify, Inc. has faced significant challenges, with a market cap of US$31.41 million and revenues from its Direct Marketing segment totaling US$86.44 million. Despite an experienced board and management team, the company remains unprofitable with a negative return on equity of -83.41%. Recent efforts to raise capital include filing for follow-on equity offerings and entering private placements, though some offerings were withdrawn or adjusted. Giftify's short-term assets exceed long-term liabilities but fall short of covering immediate obligations, indicating liquidity concerns despite improvements in shareholder equity over five years. The stock exhibits high volatility compared to broader markets.

• Click here to discover the nuances of Giftify with our detailed analytical financial health report.
• Review our historical performance report to gain insights into Giftify's track record.

PodcastOne (NasdaqCM:PODC)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: PodcastOne, Inc. operates as a podcast platform and publisher with a market cap of $55.72 million.

Operations: The company generates revenue of $47.46 million from its Internet Information Providers segment.

Market Cap: $55.72M

PodcastOne, Inc., with a market cap of US$55.72 million, is trading well below estimated fair value but remains unprofitable with a negative return on equity. Despite its financial challenges, the company has no long-term debt and maintains sufficient cash runway for over three years due to positive free cash flow. Recent expansions include new podcast partnerships and the launch of PodcastOne Pro, enhancing its service offerings and network reach. However, shareholder dilution occurred in the past year, and share price volatility remains high. Revenue is forecasted to grow by 17% annually with an expected fiscal 2025 revenue of at least US$51 million.

• Take a closer look at PodcastOne's potential here in our financial health report.
• Review our growth performance report to gain insights into PodcastOne's future.

Neumora Therapeutics (NasdaqGS:NMRA)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for brain diseases and neuropsychiatric and neurodegenerative disorders, with a market cap of approximately $382.90 million.

Operations: No revenue segments have been reported for this clinical-stage biopharmaceutical company.

Market Cap: $382.9M

Neumora Therapeutics, Inc., with a market cap of US$382.90 million, is pre-revenue and unprofitable, facing increased losses over the past five years. Despite this, the company remains debt-free with short-term assets of US$348.6 million exceeding liabilities and has an experienced board. Recent Phase 3 trial results for navacaprant did not meet primary endpoints but showed safety and tolerability, impacting its growth prospects in major depressive disorder treatment. The stock trades significantly below estimated fair value but has seen shareholder dilution and high share price volatility recently.

• Get an in-depth perspective on Neumora Therapeutics' performance by reading our balance sheet health report here.
• Explore Neumora Therapeutics' analyst forecasts in our growth report.

Make It Happen

• Discover the full array of 728 US Penny Stocks right here.
• Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments.
• Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free.

Contemplating Other Strategies?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com